The BioPharm Brief: Oncology Innovations Continue with Durable Survival, In Vivo CAR-T, and Combination Therapies

Welcome to The BioPharm Brief, your daily snapshot of the latest developments shaping biopharmaceutical research, clinical progress, and regulatory strategy. Today’s update highlights advances in oncology across rare cancers, immunotherapy combinations, and strategic acquisitions aimed at next-generation cell therapy platforms.

New data from Immunocore reinforce the long-term clinical impact of tebentafusp in metastatic uveal melanoma, a rare and historically difficult-to-treat cancer. Five-year overall survival findings from a phase 3 trial show sustained benefit, building on earlier evidence that established tebentafusp as the first therapy to demonstrate a meaningful survival advantage in this patient population. These results highlight the growing importance of T-cell receptor–based immunotherapies in addressing tumors that have shown limited response to conventional checkpoint inhibitors.

In parallel, Eli Lilly and Company announced plans to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies, signaling continued investment in next-generation cell engineering approaches. Unlike traditional ex vivo CAR-T therapies, in vivo strategies aim to generate engineered immune cells directly within the patient’s body, potentially simplifying manufacturing and expanding access. The move reflects broader industry efforts to improve scalability and reduce complexity in cell therapy development.

Meanwhile, FDA has granted priority review to the combination of Padcev, an antibody-drug conjugate, and Keytruda, a PD-1 inhibitor, for the treatment of muscle-invasive bladder cancer. The application is supported by phase 3 data demonstrating statistically significant improvements in event-free and overall survival, with the potential to establish a new perioperative standard of care if approved. The agency has set a target decision date of Aug. 17, 2026.

Taken together, these developments reflect a significant shift in oncology toward combination strategies, durable survival outcomes, and platform innovations designed to expand patient access to advanced therapies.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Summary of key developments

• Tebentafusp demonstrates durable 5-year survival benefit in metastatic uveal melanoma.
• Lilly’s acquisition strategy highlights momentum in scalable in vivo CAR-T therapies.
• FDA priority review for Padcev plus Keytruda underscores progress in bladder cancer combination treatment.